Filing Flows › International Stem Cell (ISCO) › Q1 2026 › vs Q1 2025
International Stem Cell (ISCO) Q1 2026 vs Q1 2025 (year over year)
International Stem Cell's revenue rose $186K (+9%) from $2.1M in Q1 2025 to $2.3M in Q1 2026. The biggest changes: Biomedical Market +$175K (+9%); Anti Aging Skincare Market +$11K (+8%).
International Stem Cell, Q1 2026: revenue $2.3M (+9% year over year), operating margin -8.2%, net loss $220K, operating cash flow $121K. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 4.2% | 10.4% | -6.2 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Biomedical Market | $2.2M | $2.0M | $175K | +9% |
| Anti Aging Skincare Market | $145K | $134K | $11K | +8% |
| Revenue | $2.3M | $2.1M | $186K | +9% |
| Net loss | $220K | $256K | −$36K | -14% |
| Costs & expenses | $2.5M | $2.4M | $150K | +6% |
| Operating costs | $2.5M | $2.3M | $161K | +7% |
| Interest & other, net | $30K | $41K | −$11K | -27% |
| Cost of revenue | $954K | $992K | −$38K | -4% |
| Research & development | $156K | $187K | −$31K | -17% |
| Sales & marketing | $273K | $273K | $0 | 0% |
| General & admin | $1.1M | $892K | $230K | +26% |
| Operating cash sources | $341K | $483K | −$142K | -29% |
| Depreciation & amortization | $34K | $55K | −$21K | -38% |
| Share-based compensation | $64K | $100K | −$36K | -36% |
| Working capital & other | $243K | $328K | −$85K | -26% |
| Net loss absorbed | $220K | $256K | −$36K | -14% |
| Operating cash flow | $121K | $227K | −$106K | -47% |
| Free cash flow (OCF − capex) | $98K | $222K | −$124K | -56% |
| Capital expenditures | $23K | $5K | $18K | +360% |
Questions
How much did International Stem Cell's revenue grow year over year in Q1 2026?
International Stem Cell's revenue rose $186K (+9%) from $2.1M in Q1 2025 to $2.3M in Q1 2026.
What drove International Stem Cell's revenue change in Q1 2026?
Biomedical Market +$175K (+9%); Anti Aging Skincare Market +$11K (+8%).